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ABSTRACT 22 
Study question: Do children born after donor assisted reproductive technology (ART) have an 23 
increased risk of developing childhood cancer in comparison to the general population?  24 
Summary answer: This study showed no overall increased risk of childhood cancer in individuals 25 
born after donor ART.  26 
What is known already: Most large population based studies have shown no increase in overall 27 
childhood cancer incidence after non-donor ART; however other studies have suggested small 28 
increased risks in specific cancer types, including haematological cancers. Cancer risk specifically in 29 
children born after donor ART has not been investigated to date.  30 
Study design, size, duration: This retrospective cohort study utilized record linkage to determine the 31 
outcome status of all 12,186 children born in Great Britain (1992-2008) after donor ART. The cohort 32 
included  12,137 members contributed 95,389 person-years of follow-up (average follow-up 7.86 33 
years).  34 
Participants, setting, methods: Records of all children born in Great Britain (England, Wales, 35 
Scotland) after all forms of donor ART (1992-2008) were linked to the UK National Registry of 36 
Childhood Tumours (NRCT) to determine the number who subsequently developed cancer by 15 37 
years of age, by the end of 2008. Rates of overall and type specific cancer (selected a priori) were 38 
compared with age, sex and calendar year standardised population-based rates, stratifying for 39 
potential mediating/moderating factors including sex, age at diagnosis, birth weight, multiple births, 40 
maternal previous live births, assisted conception type, and fresh/ cryopreserved cycles. 41 
Main results and the role of chance: In our cohort of 12,137 children born after donor assisted 42 
reproductive technology (52% male, 55% singleton births),  no overall increased risk of cancer was 43 
identified. There were 12 cancers detected compared to 14.4 expected (standardised incidence ratio 44 
(SIR) 0.83; 95% confidence interval (CI) 0.43-1.45; P=0.50). A small, significant increased risk of 45 
hepatoblastoma was found, but the numbers and absolute risks were small (<5 cases observed; SIR 46 
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10.28; 95%CI 1.25-37.14; P<0.05). This increased hepatoblastoma risk was associated with low 47 
birthweight. 48 
Limitations, reasons for caution: Although this study includes a large number of children born after 49 
donor ART, the rarity of specific diagnostic sub-groups of childhood cancer results in few cases and 50 
therefore wide confidence intervals for such outcomes.  As this is an observational study, it is not 51 
possible to adjust for all potential confounders; we have instead used stratification to explore 52 
potential moderating and mediating factors, where data were available.  53 
Wider implications of the findings: This study is the first to investigate cancer risk in children born 54 
after donor ART. Although based on small numbers, results are reassuring for families and clinicians. 55 
The small but significant increased risk of hepatoblastoma detected was associated with low 56 
birthweight, a known risk factor for this tumour type. It should be emphasised that the absolute risks 57 
are very small.  However, an on-going investigation with a longer follow-up is needed.  58 
Study funding/competing interest(s): This work was funded by Cancer Research UK 59 
(C36038/A12535) and the National Institute for Health Research (405526) and supported by the 60 
National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital 61 
for Children NHS Foundation Trust and University College London. The work of the Childhood Cancer 62 
Research Group (CCRG) was supported by the charity CHILDREN with CANCER UK, the National 63 
Cancer Intelligence Network, the Scottish Government and the Department of Health for England 64 
and Wales.  There are no competing interests.  65 
Trial registration number: N/A 66 
 67 
Key Words: childhood cancer, assisted reproductive technology, donor treatment, cohort study, 68 
epidemiology, data linkage. 69 
 70 
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INTRODUCTION 72 
Donor ART treatment cycles utilize donor sperm, oocytes or embryos and result in approximately 10% 73 
of all births after ART in the UK (Human Fertilisation & Emryology Authority 2013). Given that most 74 
donors have few, if any, fertility problems, children born after donor ART represent a subtly different 75 
population than children born after non-donor ART.  This inherent difference, together with the 76 
increasing use of donor ART cycles and the extra uncertainty faced by couples using donor gametes, 77 
places greater importance on follow-up studies differentiating between children born after donor 78 
and non-donor ART.   79 
The possibility of an increased risk of childhood cancer in individuals born after ART has been 80 
suggested previously (Hargreave et al. 2013; Puumala et al. 2012; Schieve et al. 2004; Sutcliffe and 81 
Ludwig 2007; Kallen et al. 2010).  Systematic reviews have provided conflicting evidence (Raimondi, 82 
Pedotti, and Taioli 2005; Hargreave et al. 2013; Reigstad et al. 2017), with a recent meta-analysis 83 
suggesting a small but significant increased risk of cancer in children born after ART (Relative Risk 84 
1.33; 95%CI 1.08-1.63) (Hargreave et al. 2013). Two large, population based studies, published since, 85 
reported no overall increased risk and no increased risk in haematological cancers (Sundh et al. 2014; 86 
Williams et al. 2013). However, these studies did not include children born after donor ART (Sundh 87 
et al. 2014; Williams et al. 2013).  A further, smaller, population based study showed no overall 88 
increased risk of childhood cancer, but did find a significant increase in leukaemia and Hodgkin 89 
lymphoma (Reigstad et al. 2016).  This study did include some children born after donor ART but did 90 
not estimate risk in this group separately (Reigstad et al. 2016).  91 
We conducted a large population-based linkage study, aiming to provide risk estimates for childhood 92 
cancer overall and for specific diagnostic subgroups (chosen a priori), in individuals born after donor 93 
ART.  94 
 95 
MATERIALS AND METHODS 96 
Population and cohort participants  97 
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All records relating to 12,186 children born between January 1st 1992 and December 31st 2008 in 98 
Great Britain (England, Wales and Scotland) after donor ART were identified by the Human 99 
Fertilization and Embryology Authority (HFEA). Donor ART is defined as ‘all treatments or procedures 100 
including in-vitro handling of both human oocytes and sperm, or embryos, for the purpose of 101 
establishing a pregnancy’ using donor oocytes, sperm or embryos (Zegers-Hochschild et al. 2009). 102 
The HFEA is legally required to record treatment and outcome details of all ART cycles in the UK, 103 
including those using donor gametes or embryos. Thus the dataset is considered effectively 104 
complete (HFEA act 2008).  105 
 106 
Ethical approval 107 
Approval for the study was obtained from the National Information Governance Board and the 108 
London Research Ethics Committee including approval for the restricted use of data without 109 
individual written informed consent. One of the conditions attached to approval of this study 110 
prevents the publication of cells containing less than five individuals. Patients can withdraw consent 111 
for their HFEA data to be used for research.  At the time of the study, 0.3% of all families using ART 112 
had done so; their data were not included. 113 
 114 
Outcome data  115 
Details of cancer incidence were obtained from the National Registry of Childhood Tumours (NRCT).  116 
During the study period, the NRCT was the largest national population-based childhood cancer 117 
registry world-wide, ascertaining validated information from multiple sources about children, under 118 
15 years, diagnosed with cancer in the UK (Kroll et al. 2011). The NRCT is considered almost 119 
complete for the study period(Kroll et al. 2011). The International Classification of Childhood Cancer 120 
3
rd
 edition (ICCC3), was used to categorise cancers (Steliarova-Foucher et al. 2005). Co-morbidities, 121 
known at the time of a child’s cancer diagnosis, were reported to the NRCT by the registering 122 
oncology centre, and data are reasonably complete for major congenital anomalies. 123 
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 124 
Data linkage 125 
Ethical regulations stipulated that identifiable data were only viewed directly by HFEA staff. 126 
Therefore data linkage was undertaken by two members of HFEA staff independently from each 127 
other, following a robust data linkage protocol, developed to maximize linkage sensitivity and 128 
specificity, used and described in another similar study (Williams et al. 2013). Linkage was directly 129 
overseen by CLW, KJB and BB. A total of 12,186 eligible HFEA records of children born after donor 130 
ART 1992-2008 were linked to all 14,896 NRCT eligible records of children documented as having 131 
been born 1992-2008, and having developed cancer before January 1st 2009. All potential matches 132 
using this inclusive linkage protocol were anonymously reviewed by CLW and KJB. BB reviewed any 133 
cases where the validity of the match was questionable (n=2, both unanimously rejected by all three 134 
reviewers).  135 
 136 
Statistical analyses and calculation of expected rates  137 
Person-years at risk were calculated from date of birth until the soonest of cancer diagnosis date, 138 
December 31, 2008 or the child’s 15
th
 birthday. There were 49 children (0.4%) excluded from the 139 
analyses as no valid date of birth was available and therefore person-years at risk could not be 140 
determined. Expected cancers in the cohort were calculated by multiplying person-years at risk by 141 
the corresponding national incidence rates (1-year age bands by calendar year and sex) for children 142 
born and diagnosed in Great Britain. Standardized Incidence Ratios (SIR) were calculated comparing 143 
observed cancers within the cohort to expected values. Exact 95% confidence intervals and two-144 
sided P values were calculated assuming a Poisson distribution (Breslow and Day 1987). Analyses 145 
were performed using STATA software, version 12 (Stata Corp 2013). 146 
 147 
 148 
RESULTS 149 
Page 6 of 20
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
 7 
 
Included in this study were 12,137 children who contributed 95,389 person-years follow-up, with an 150 
average duration of 7.86 years. Cohort demographics are detailed in Table 1.  151 
 152 
Twelve children were linked to NRCT records and therefore identified as having developed cancer. 153 
Baseline demographics appeared broadly similar for cohort members who did and did not develop 154 
cancer (data not shown separately given the small numbers). The median age at cancer diagnosis 155 
was 2.6 years (inter-quartile range 1.2-5.2). There were no children with more than one cancer 156 
diagnosis. There were 14.4 cancers expected within the cohort, resulting in an unadjusted SIR of 0.83 157 
(95% CI 0.43-1.45; Table 2). Sensitivity analysis including the two potential cases rejected during 158 
data-linkage did not substantially alter the results (SIR 0.97; 95% CI 0.53- 1.63; data not shown). The 159 
results did not change appreciably when stratified by sex, age at diagnosis, birthweight, birth 160 
multiplicity, maternal parity, type of ART, and fresh versus cryopreserved embryos (Table 2), 161 
although the small number of events in some strata have resulted in wider confidence intervals.      162 
 163 
No significant excess risk was seen for any major ICCC3 category, with the exception of hepatic 164 
tumours (Table 3). A significant excess of hepatic tumours was detected (SIR 9.12; 95%CI 1.11-32.95; 165 
Table 3), all of which were hepatoblastomas (SIR 10.28; 95%CI 1.25-37.14; Table 3; Absolute excess 166 
risk 18.66 per million person-years at risk, 95%CI 0.24-73.39). This excess was associated with low 167 
birthweight and was only seen in children with birthweight <2500g (SIR 28.00; 95%CI 3.39-101.14; P= 168 
0.02; data not shown).  169 
 170 
DISCUSSION 171 
No overall increased risk of childhood cancer was detected in this large and complete national 172 
population based cohort of children born after donor ART. This is in line with two similar recently 173 
published cohort studies of children born after non-donor ART (Sundh et al. 2014; Williams et al. 174 
2013). The recently published study combining data on 91,796 children born after non-donor ART in 175 
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four Nordic countries found no significant increase in overall cancer rates (adjusted Hazard Ratio 176 
1.08; 95%CI 0.91-1.27) (Sundh et al. 2014). Similarly our previous study of 106,013 children born 177 
after non-donor ART over the same study period and from the same population as our current study, 178 
did not show an overall increased risk of cancer (SIR 0.98; 95%CI 0.81-1.19) (Williams et al. 2013). 179 
 180 
This study is the first, to our knowledge, to explore cancer risk in children born after donor ART and 181 
uses high quality data from two population-based data sets. NRCT data are virtually complete for the 182 
study period (Kroll et al. 2011) and reporting to the HFEA is mandatory (HFEA act 2008). Whilst this 183 
study is the first to investigate cancer risk after donor ART, it is based on previously published 184 
methodology (Williams et al. 2013).  There were very few cases with uncertain linkage (n=2), and 185 
sensitivity analysis including these did not substantially alter results.  186 
 187 
Although this is a population-based study covering the whole of Great Britain over a 17 year time 188 
period which includes a large number of children born after donor ART, the rarity of specific 189 
diagnostic sub-groups of childhood cancer and thus the small number of cases reported in this study 190 
result in wide confidence intervals for individual outcomes. As this is an observational study, it is not 191 
possible to adjust for all potential confounders. We have instead used stratification to explore the 192 
role of a number of potential moderating and mediating factors, where data are available. 193 
Additionally, this study was not able to compensate for deaths and emigrations within this cohort. 194 
However, given the age of the cohort and extrapolating from national data (Office for National 195 
Statistics 2010), we would estimate under normal circumstances not more than 69 members of the 196 
original cohort would have died during follow-up (0.6%). Emigration rates are harder to estimate, 197 
but we assume not more than 2% are likely to have emigrated during follow-up. It was not possible 198 
to adjust for socio-economic status (SES) as no measure of SES was available for the cohort as a 199 
whole. It is also possible that there were other unknown potential confounding factors, which we 200 
were unable to take into account. Whilst the overall numbers of children born after oocyte donation, 201 
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sperm donation or embryo donation were available, these data were not available for analysis at an 202 
individual level.  Our study had an average follow-up of 7.86 years. Therefore we are not able to 203 
comment definitively on risk of cancer subtypes with a peak age of onset beyond 7 years.    204 
 205 
A significantly increased risk of hepatoblastoma was detected in this study of children born after 206 
donor ART, and was associated with low birthweight. A similar increased risk of hepatoblastoma, 207 
associated with low birthweight, was seen in our previous study of children born after non-donor 208 
conception (SIR 3.64; 95% CI 1.34-7.93) (Williams et al. 2013). The Nordic group found a 2- fold 209 
increase risk of hepatic tumours in children born after non-donor ART; although this was based on 210 
small numbers and confidence intervals were wide and included 1, they did find a hazard ratio of 211 
2.61 (aHR2.61 (0.74-9.26; adjusted for country, maternal age, parity, sex, gestational age and birth 212 
defects) (Sundh et al. 2014). Beckwith-Wiedemann syndrome (BWS) is also a risk factor for 213 
hepatoblastoma (Puumala et al., 2012), and children born after ART are at increased risk of BWS 214 
(Amor and Halliday 2008).  There was a small number of children (less than five) in our cohort with 215 
BWS, but there were no cases of hepatoblastoma in children with BWS or related anomalies.  216 
 217 
There is a known, consistent, inverse association between birth weight and hepatoblastoma risk 218 
(O'Neill et al. 2015; Heck et al. 2013; de Fine Licht et al. 2012; Ansell et al. 2005; Spector et al. 2009; 219 
Spector et al. 2008; Ikeda, Matsuyama, and Tanimura 1997; McLaughlin et al. 2006; Tanimura et al. 220 
1998). Children born after ART are known to have significantly lower birth weight than children born 221 
after spontaneous conception (McDonald et al. 2010; Helmerhorst et al. 2004).   Unfortunately as we 222 
were unable to adjust for birth weight, instead stratifying for this factor in both studies, we are 223 
unable to determine whether children in these studies have increased risk of hepatoblastoma 224 
mediated solely due to their low birth weight or whether children with low birth weight born after 225 
ART are at higher risk than they would be if born after spontaneous conception. The Nordic study did 226 
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not adjust for birth weight directly, but adjusted for gestational age, which did not materially alter 227 
their rate estimate for hepatic tumours (Sundh et al. 2014).   228 
 229 
In conclusion, this study provides evidence against an increased risk of overall childhood cancer in 230 
individuals born after donor ART, which is reassuring for parents and clinicians alike. For the majority 231 
of individual diagnostic subgroups, risk estimates were not significantly raised. A significant 232 
increased risk of hepatoblastoma was observed, in line with that found in our recent study of 233 
children born after non-donor ART. This was associated with low birth weight, itself a known risk 234 
factor for hepatoblastoma. Although this finding was not observed in non-UK studies (Sundh et al. 235 
2014; Kallen et al. 2010), further investigation is warranted.  However it should be emphasised that 236 
the absolute risks are very small.  237 
  238 
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Table I. Cohort Characteristics.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Frequency (%)
1
 
 
N 12,186 
Sex  
Male 6,326 (52) 
Female 5,851 (48) 
Multiple births  
Singletons 6,697 (55) 
 Multiple Births 5,489 (45) 
Birth weight  
Mean (SD) g 2,807 (812) 
Birth weight group (g)  
≤2499 3,980 (33) 
2500g-3999 7,379 (61) 
≥4000 679 (6) 
Gestational age at birth  
Mean (SD) 37.1 (3.3) 
Type of donor treatment  
Donated oocytes 5209 (43) 
Donated sperm 6508  (53) 
Donated embryos 469 (4) 
Type of ART  
IVF 9,764 (80) 
ICSI and other micromanipulation
2
 2,110 (17) 
Not recorded 310 (3) 
Fresh/ frozen cycles  
Fresh Cycle 10,207 (84) 
Cryopreserved Cycle 1,949 (16) 
Stage at embryo transfer  
Blastocyst 5,402 (44) 
Cleavage 370 (3) 
Not recorded 6,414 (53) 
Maternal age at birth of child  
Mean (SD) years 37.8 (6.2) 
Paternal age at birth of child  
Mean (SD) Years 40.3 (7.4) 
Infertility cause  
Both Male & Female 2,734 (22) 
Female Factor only 2,847 (23) 
Male Factor only 4,706 (39) 
Unexplained 740 (6) 
Not recorded 1,159 (10) 
Duration of infertility  
Mean (SD) years 6.1 (4.1) 
Previous maternal ART cycles  
0 4,799 (39) 
≥1  7,385 (61) 
Previous maternal live births  
 0 2,546 (21) 
≥1  2,535 (21) 
Unknown 7,105 (58) 
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1
Frequencies do not always add up to 12,186, and percentages to 100, where data is unrecorded and treated as missing 
 
2
Intracytoplasmic sperm injection (ICSI): a procedure in which a single spermatozoon is injected into the oocyte cytoplasm; 
Micromanipulation: a technology that allows micro-operative procedures to be performed on the spermatozoon, oocyte, 
zygote, or embryo. 
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Table II. Overall cancer risk stratified by potential mediating/moderating factors.  
Mediating/ Moderating Factor 
All Cancers
1
 
Person years 
follow-up 
SIR 95% CI 
Overall 95,389 0.83 0.43-1.45 
Sex    
Male 49,418 1.13 0.52-2.14 
Female 45,970 0.47 0.10-1.36 
Age group at diagnosis (years)    
0 11,734 1.29 0.27-3.78 
1-4 38,917 0.82 0.30-1.79 
5-9 31,688 0.82 0.18-2.57 
10-14 13,051 0.00 0.00-2.14 
Birth weight (g)    
<2500 33,048 0.80 0.22-2.05 
2500g-3999 56,398 0.93 0.40-1.84 
≥4000 4,776 0.00 0.00-4.00 
Multiple Births    
Singletons 50,331 0.91 0.37-1.87 
Multiple Births 45,058 0.74 
0.24-1.73 
 Previous maternal live births    
0 18,940 1.04 0.21-3.03 
1 or more 21,165 0.62 0.08-2.25 
Type of ART    
IVF 83,548 0.89 0.44-1.58 
ICSI and other micromanipulation 10,083 0.00 0.00-1.76 
Not recorded 1,734 3.26 0.08-18.2 
Fresh/ 
Cryopreserved cycle 
   
Fresh 80,153 0.83 0.40-1.52 
Cryopreserved 14,830 0.88 0.11-3.18 
Not recorded 406 0.00 0.00-55.7 
 
1
Numbers of cancers observed not given, as ethical regulations preclude publishing cells containing fewer than five cohort 
members. 
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Table III. Cohort cancer risk by specific cancer type.  
Cancer Type and ICCC3 categories
2
 
Person years of 
follow up 
Standardized 
Incidence Ratio
1
 
95% Confidence 
Interval 
All cancers    
ICCC-3 groups I to X11 95,389 0.83 0.43-1.45 
Leukaemia    
ICCC-3 group I 95,445 0.61 0.13-1.78 
CNS tumours    
ICCC-3 group III 95,435 1.17 0.32-2.99 
Neuroblastoma    
ICCC-3 group IV 95,464 0 0.00-2.03 
Retinoblastoma    
ICCC-3 group V 95,452 3.29 0.40-11.87 
Renal tumours    
ICCC-3 group VI 95,460 0.94 0.02-5.25 
Hepatic  tumours    
All- ICCC-3 group VII 95,454 9.12 1.11-32.95* 
Hepatoblastoma, ICCC-3 group VIIa 95,454 10.28 1.25-37.14* 
Bone tumours and extra osseous 
sarcomas 
   
All- ICCC-3 groups VIII and IX 95,464 0 0.00-2.50 
Osteosarcoma- ICCC-3 group VIIIa 95,464 0 0.00-18.38 
Ewing’s Sarcoma- ICCC-3 group-VIIIc, IXd, 
division 1& 2 
95,464 0 0.00-12.41 
Rhabdomyosarcoma- ICCC-3 group IXa 95,464 0 0.00-5.91 
Other Sarcomas- ICCC-3  groups VIIIb, 
VIIId, VIIIe  IXb, IXc, IXd divisions 3 to 11, 
IXe 
95,464 0 0.00-10.45 
Germ cell tumours    
ICCC-3 group X 95,464 0.00 0.00-6.59 
 
1
Numbers of cancer observed not given, as ethical regulations preclude publishing cells containing fewer than five cohort 
members. 
2
Cancer type classified according to ICCC3 coding
29
 
* = P<0.05. ** =P<0.01*** =P<0.001 
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